GlaxoSmithKline (GSK) is a global pharmaceutical company with a diversified portfolio of biologics, small molecules and consumer healthcare products. In Oncology GSK’s pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. The company was formed in 2000 as a result of merger between GlaxoWellcome plc and SmithKline Beecham.
- In Dec 2018, GlaxoSmithKline acquired TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, in approx. $5.1 billion (£4.0 billion), with a major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor.
- In May 2013, GSK acquired Okairos AG, developer of vaccine platform technologies, for $325 million USD in cash.
- In Aug 2012, GSK acquired Human Genome Sciences (HGS) for approx. $3.6 billion USD on an equity basis or approx. $3 billion USD net of cash and debt.
- In May 2005, GSK acquired Corixa Corporation developing drugs for autoimmune, infectious diseases and cancer in $314 Mn USD. At the time of acquisition Corixa pipeline includes Tositumomab/Bexxar®, FDA approved for follicular non-Hodgkin lymphoma.
Page 1 of 3
